Glioma Clinical Trials

At Memorial Sloan Kettering, we are constantly working to improve our treatment strategies and extend survival for people with a glioma. This includes making advances in surgery and radiation therapy, as well as developing new drug therapies.

Gliomas tend to vary in makeup. A treatment that works against some cells might not work against others. Our scientists are also making progress in understanding the genetic subtypes of glioblastomas. This research is enabling better classification of these tumors according to their underlying biology. The ultimate goal is to create focused drugs that can target specific mutations.

At MSK, we use precision medicine in our treatment of gliomas. All MSK patients have access to a test called MSK-IMPACT™. This can determine if a tumor has mutations that make it eligible for targeted therapies. We have seen dramatic responses to drugs that attack a unique genetic vulnerability in a tumor. These medicines are commercially available or available through clinical trials.

Nearly every treatment that is available today exists because of a clinical trial. MSK currently has several open clinical trials testing new drugs and therapies for people with a glioma. In addition to our main location in Manhattan, we have neuro-oncologists at MSK regional sites, where we also offer clinical trials.

Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

For a list of available clinical trials for gliomas, visit our clinical trial finder.

and/or
14 Clinical Trials found
A Clinical Trial to Evaluate Multiple Treatment Regimens for Newly Diagnosed Recurrent Glioblastoma (GBM AGILE)
The purpose of this study is to evaluate the effectiveness of treating patients with recurrent and newly diagnosed glioblastoma using new therapies that are thought to be effective for treating brain cancer. The new therapies available as part of this clinical trial include regorafenib, VAL-083, and paxalisib.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of 177Lu-PSMA-617 in People With Gliomas
Researchers want to learn if the radiopharmaceutical therapy 177Lu-PSMA-617 is a safe treatment for people with glioma. Radiopharmaceutical therapy delivers radiation directly into a tumor to destroy cancer cells.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of Debio 0123 With Temozolomide for People With Glioblastoma
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of rQNestin34.5v.2 in People With Glioma
Researchers are assessing a drug called rQNestin34.5v.2, for people with brain cancer that came back after treatment. The people in this study have a type of brain cancer called a glioma.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of TNG456 in People With Advanced Glioblastoma
Researchers want to find the best dose of TNG456 to use alone or with abemaciclib to treat brain cancer. The people in this study have glioblastoma that has spread. In addition, their cancer is missing a protein called MTAP.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
New York City
A Phase 1b Study of ABBV-637 or ABBV-155 With ERAS-801 or Standard Therapy for People With Glioblastoma
This study is assessing ABBV-637 and ABBV-155 with ERAS-801 or standard treatment in people with glioblastoma. The people in this study have newly diagnosed glioblastoma or glioblastoma that returned after treatment and can be surgically removed. In addition, their tumors have a mutation (change) in the EGFR gene.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Safusidenib in People With Glioma
Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Vorasidenib and Temozolomide in People With Grade 4 Glioma
Researchers are seeking the best doses of vorasidenib and temozolomide to treat glioma and assessing how well they work together. The people in this study have grade 4 gliomas with a mutation (change) in the IDH1 or IDH2 gene. These mutations can cause cancer cells to multiply and spread.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I Study of Vorasidenib with Pembrolizumab Immunotherapy for Recurrent or Persistent IDH-1 Mutant Astrocytomas
The purpose of this study is to find the highest dose of vorasidenib that can be given safely in combination with pembrolizumab immunotherapy in people with astrocytoma that came back or continued to grow despite treatment and contains a mutation in the IDH-1 protein.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau